Swiss National Bank lifted its stake in Aduro BioTech Inc (NASDAQ:ADRO) by 27.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,300 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the period. Swiss National Bank owned 0.09% of Aduro BioTech worth $513,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. increased its stake in shares of Aduro BioTech by 10.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 164,071 shares of the biotechnology company’s stock valued at $1,526,000 after buying an additional 14,863 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of Aduro BioTech by 58.9% in the first quarter. Baillie Gifford & Co. now owns 1,656,737 shares of the biotechnology company’s stock valued at $15,408,000 after buying an additional 614,124 shares in the last quarter. Artal Group S.A. increased its stake in shares of Aduro BioTech by 175.0% in the first quarter. Artal Group S.A. now owns 550,000 shares of the biotechnology company’s stock valued at $5,115,000 after buying an additional 350,000 shares in the last quarter. DRW Securities LLC increased its stake in shares of Aduro BioTech by 160.0% in the first quarter. DRW Securities LLC now owns 26,000 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 16,000 shares in the last quarter. Finally, Sofinnova Ventures Inc acquired a new stake in shares of Aduro BioTech in the first quarter valued at $155,000. Hedge funds and other institutional investors own 49.01% of the company’s stock.
Aduro BioTech stock opened at $6.40 on Thursday. Aduro BioTech Inc has a 12-month low of $5.10 and a 12-month high of $11.55.
Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. The business had revenue of $2.64 million for the quarter, compared to analysts’ expectations of $3.74 million. Aduro BioTech had a negative return on equity of 44.97% and a negative net margin of 574.11%. analysts anticipate that Aduro BioTech Inc will post -1.25 EPS for the current year.
In other Aduro BioTech news, insider Stephen T. Isaacs sold 24,143 shares of the firm’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $6.50, for a total transaction of $156,929.50. Following the transaction, the insider now owns 356,996 shares in the company, valued at $2,320,474. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Elsas Andrea Van sold 10,454 shares of the firm’s stock in a transaction dated Tuesday, July 17th. The stock was sold at an average price of $6.96, for a total value of $72,759.84. Following the transaction, the insider now owns 206,215 shares in the company, valued at approximately $1,435,256.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,352 shares of company stock worth $832,661. 5.00% of the stock is owned by company insiders.
A number of analysts have recently weighed in on the company. BidaskClub lowered Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Canaccord Genuity restated a “buy” rating and issued a $30.00 target price on shares of Aduro BioTech in a research note on Thursday, August 2nd. ValuEngine upgraded Aduro BioTech from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 30th. Bank of America decreased their price target on Aduro BioTech from $8.00 to $6.00 and set an “underperform” rating on the stock in a report on Thursday, August 2nd. Finally, HC Wainwright set a $10.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Thursday, August 2nd. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $13.67.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Read More: Earnings Per Share
Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro BioTech Inc (NASDAQ:ADRO).
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.